CNBC·3 min read·medium
Samsung Biologics to buy Swiss PolyPeptide Group in $1.8 billion deal
J
Jenny Lee
✦AI Summary
Samsung Biologics has made an all-cash bid of $1.8 billion to acquire the Swiss-based PolyPeptide Group. The deal aims to expand Samsung's capabilities in peptide therapeutics, particularly for obesity and diabetes treatments.
South Korea's Samsung Biologics said on Monday that it had made an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) for Switzerland's PolyPeptide Group , which specializes in peptide-based active pharmaceutical ingredients.
businesshealthtechnology
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in